R&D News | pharmaphorum

News

Lynparza on cusp of approval for advanced ovarian cancer

Breast cancer drug Lynparza (olaparib) is poised for EU approval for the first-line treatment of a certain type of metastatic ovarian cancer.

News

Blow for Gilead as another NASH trial fails

Gilead's attempts to find a treatment for nonalcoholic steatohepatitis (NASH) have been dealt another blow after another trial failure for one of its prime candidates to treat the disease.<

News

UK government hopes CRO cash will boost life sciences

Research and development in the UK will have a major boost thanks to the Medicines Discovery Catapult today launching 22 partnerships with UK-based contract research organisations (CRO

News

Biogen's R&D strategy fails to impress after Alzheimer's tri...

The dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s drug aducanumab, and in its latest Q1 figures the company hoped

News

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

Fulcrum repurposes failed GSK drug for rare disease

GSK’s failed cardiovascular drug losmapimod looks like it might get a new lease of life after being picked up by biotech Fulcrum Therapeutics, who want to repurpose the drug to treat the ra

News

Second death in gene therapy trial prompts investigation

A second death in a study of Novartis’ spinal muscular atrophy gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) – a potential blockbuster for this rare disease – has prompte

Lynparza on cusp of approval for advanced ovarian cancer

Blow for Gilead as another NASH trial fails

UK government hopes CRO cash will boost life sciences

Biogen's R&D strategy fails to impress after Alzheimer's tri...

Fulcrum repurposes failed GSK drug for rare disease

Second death in gene therapy trial prompts investigation

Bayer plans filings for cardiac amyloidosis imaging agent

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks